
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a leader in the insulin delivery and diabetes management industry, backed by a strong pipeline of innovative products and a global presence. Despite facing competition and regulatory risks, the company is expected to achieve steady revenue growth and improved profitability margins, as evidenced by their high Time in Range (TIR) and praise from physicians for their AID systems. The company's strong balance sheet and progress in exiting agreements with Medtronic further reinforce a positive outlook for MiniMed.
Bears say
Minimed Group is currently facing several challenges in the market, including intense competition, potential pricing pressure, and shifting market dynamics. Additionally, the company's profitability profile and cash generation capabilities, while compelling, may be hindered by factors such as inflationary input costs and CGM pricing pressures. The success of MiniMed's new product launches will be crucial in regaining a competitive advantage in the fast-moving diabetes tech segment, and the company's close relationship with Medtronic, which still holds a majority ownership, poses potential risks.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares